Navigation Links
Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
Date:3/10/2008

SAN DIEGO, March 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that complete safety data from its registrational bioequivalence clinical study of ANX-530 (vinorelbine emulsion) will be published in the 2008 Proceedings of the American Society of Clinical Oncology (ASCO) in connection with ASCO's 2008 Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL. The abstract, entitled "Tolerability and incidence of infusion site reactions with emulsion formulation of vinorelbine (ANX-530) compared to vinorelbine solution," will be published.

ADVENTRX recently completed a registrational bioequivalence clinical study of ANX-530. Pharmacokinetic equivalence, the primary endpoint of the study, was observed between ANX-530 and Navelbine(R). Furthermore, in post hoc analyses, ANX-530 demonstrated a statistically significant reduction in injection site reactions when compared to Navelbine. ADVENTRX intends to submit to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2008 a Section 505(b)(2) NDA for ANX-530.

About ANX-530 (vinorelbine emulsion)

ANX-530 is a novel emulsion formulation of the chemotherapy drug vinorelbine. Navelbine, a branded formulation of vinorelbine, is approved in the U.S. to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non-small cell lung cancer and advanced or metastatic breast cancer. Worldwide sales of Navelbine and generic formulations of vinorelbine in 2006 were in excess of $200 million.

Navelbine and its generic equivalents are often associated with injection site reactions, including phlebitis, erythema and pain at the site of in
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
2. CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
3. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
4. Plurality Completes R&D of its HAL-256 Multicore Processor
5. First Complete Career Service for Life-Science Professionals
6. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
7. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
8. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
11. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Bryan-College Station, Texas (PRWEB) September 18, 2014 ... University System Chancellor John Sharp, Texas A&M Health ... from the U.S. Department of Health and Human ... GSK today dedicated a national pandemic influenza vaccine ... will serve as an anchor for the Texas ...
(Date:9/18/2014)... Research and Markets has announced the addition ... report to their offering. The ... and in-depth study on the current state of the ... a basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including development ...
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  MEI Pharma, Inc. ... the clinical development of novel therapies for cancer, announced today ... Executive Officer, will present at BioCentury,s NewsMakers in the ... 8:30 a.m. Eastern time from the Millennium Broadway Hotel & ... live webcast of the presentation can be accessed at ...
(Date:9/18/2014)... , Sept. 18, 2014   Sigma-Aldrich ... it has entered into a new gene editing ... School,s Vector Core. Under the partnership, Sigma-Aldrich will ... experimental design consultation, and dedicated gene editing bioinformaticians. ... gene editing-based research at the U-M Medical School. ...
Breaking Biology Technology:Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... ST. PAUL, Minn., Jan. 3 /Xinhua-PRNewswire/ --,WuXi ... provider of pharmaceutical R&D,outsourcing services, has signed ... Services, Inc. (AppTec). The acquisition of AppTec ... and expertise,gain a significant U.S. operational footprint, ...
... Pharmos Corporation,(Nasdaq: PARS ) announced today ... private placement of its 10% Convertible Debentures due ... $4,000,000 principal amount of the,Debentures, at par, and ... The purchasers consisted of certain existing investors in ...
... Jan. 3 TAP Pharmaceutical Products,Inc. today announced the ... Food and Drug Administration (FDA) for the use of ... and maintenance of,patients with erosive esophagitis and non-erosive reflux ... novel delivery system., "This compound and its novel ...
Cached Biology Technology:WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 2WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 3WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 4WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 5Pharmos Corporation Completes Initial Closing of Private Placement 2
(Date:9/17/2014)... the Copenhagen Centre for Social Evolution and Yale University ... birth weight and -length can partially predict the likelihood ... autism and schizophrenia later in life. The study analyzed ... hospital diagnoses for up to 30 years, and adjusted ... is published today in the Proceedings of the ...
(Date:9/17/2014)... first partial genome sequence of an ancient pig. Extracted ... of the Montsoriu Castle in Girona, the data obtained ... today,s Iberian pig. Researchers also discard the hypothesis that ... The study, published in Heredity , sheds new ... on that of the Iberian breed, considered to be ...
(Date:9/17/2014)... EAST LANSING, Mich. Mutations in the human retinoblastoma ... Now, Michigan State University scientists have turned to fruit ... cancer gene. , In a paper featured on ... Journal of Biological Chemistry , Michigan State University researchers ... mutations similar to those present in the human cancer ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Iberian pig genome remains unchanged after 5 centuries 2Abnormal properties of cancer protein revealed in fly eyes 2
... has found that a little-understood disease study authors are ... bee larvae, is the largest risk factor for predicting ... seen symptoms similar to IBDS associated with viruses spread ... Tarpy, an associate professor of entomology at North Carolina ...
... South Atlantic Ocean can be used to accurately forecast, ... miles away in northwestern India, a University of Michigan ... July sea surface temperatures in the tropical South Atlantic ... epidemics in the arid and semi-arid regions of northwest ...
... by researchers at the University of California, San ... produced the most comprehensive virtual reconstruction of human ... known as Recon 2, to identify causes of ... and even psychiatric and neurodegenerative disorders. Each person,s ...
Cached Biology News:Researchers id queens, mysterious disease syndrome as key factors in bee colony deaths 2Early warning system provides 4-month forecast of malaria epidemics in northwest India 2International consortium builds 'Google Map' of human metabolism 2International consortium builds 'Google Map' of human metabolism 3International consortium builds 'Google Map' of human metabolism 4